Đánh giá hiệu quả của phác đồ có bortezomib trong điều trị bước đầu đa u tủy xương tại bệnh viện K

To evaluate the effectiveness of bortezomib-containing regimens in the first line treatment of multiple myeloma at K hospital. Subjects and methods: A prospective descriptive study conducted on 44 multiple myeloma patients received bortezomib regimens chemotherapy at K Hospital from 05/2019 to 10/2021. Results: The average age of the patients was 59 years old, the male/female ratio: 1.1. The majority of patients admitted to the hospital because of bone pain 91%. Most of the patients had multiple lesions 88.6%. The most common injury site is the lumbar spine, 75%. The most common disease form is IgG Kappa 38.6%, IgG Lambda 18.2%. VRD and VTD regimens have high disease control rates (100% and 96.6%) while disease control rates of VCD regimens is 60%. The most common toxicity was peripheral neurotoxicity in the group treated with the VTD regimen 27.6%, the group treated with the VTD regimen often experienced leukopenia 40% and cutaneous toxicity 30%. Conclusion: Multiple myeloma treatment with bortezomib-containing regimens has a high response rate and safety.